Imoxtreat-LP Eye Drop is a combination ophthalmic solution containing Loteprednol etabonate 0.5% w/v, a corticosteroid with potent anti-inflammatory properties, and Moxifloxacin 0.5% w/v, a broad-spectrum fluoroquinolone antibiotic. This formulation is indicated for the treatment of ocular inflammatory conditions where bacterial infection or risk of infection is present, such as postoperative inflammation following ocular surgery, allergic conjunctivitis with secondary bacterial infection, and other inflammatory eye disorders complicated by susceptible bacterial pathogens. Loteprednol etabonate acts by inhibiting multiple inflammatory mediators, thereby reducing redness, swelling, and discomfort, while Moxifloxacin effectively inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial replication and eliminating infection. Imoxtreat-LP Eye Drop is administered topically, ensuring targeted delivery to ocular tissues with minimal systemic absorption. It is essential to use the medication as prescribed, avoiding prolonged use to reduce the risk of corticosteroid-induced ocular side effects such as increased intraocular pressure or cataract formation. Patients should be monitored regularly during therapy, and contact lenses should be removed prior to application. Imoxtreat-LP Eye Drop offers a synergistic approach to managing inflammatory and infectious ocular conditions, promoting rapid symptom relief and recovery.